WallStreetZenWallStreetZen

NASDAQ: OPTN
Optinose Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for OPTN

Based on 3 analysts offering 12 month price targets for Optinose Inc

Min Forecast
$9.00-1.85%
Avg Forecast
$9.00-1.85%
Max Forecast
$9.00-1.85%

Should I buy or sell OPTN stock?

Based on 3 analysts offering ratings for Optinose Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
3 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their OPTN stock forecasts and price targets.

OPTN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-21
lockedlocked$00.00+00.00%2025-03-21
lockedlocked$00.00+00.00%2025-03-20

1 of 1

Forecast return on equity

Is OPTN forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is OPTN forecast to generate an efficient return on assets?

Company
-7.98%
Industry
17.82%
OPTN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OPTN earnings per share forecast

What is OPTN's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$3.13
Avg 2 year Forecast
-$1.40
Avg 3 year Forecast
-$0.34

OPTN revenue forecast

What is OPTN's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$91.0M+16.36%
Avg 2 year Forecast
$113.6M+45.21%
Avg 3 year Forecast
$136.6M+74.67%
OPTN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OPTN revenue growth forecast

How is OPTN forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
20.41%
Industry
6.16%
Market
10.7%
OPTN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OPTN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OPTN vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
OPTN$9.17$9.00-1.85%Hold
BGM$11.63N/AN/A
CRDL$1.00$9.00+803.61%Buy
ASRT$0.73$3.50+382.09%Buy
INCR$1.42N/AN/A
View Top Pharmaceutical Stocks

Optinose Stock Forecast FAQ

Is Optinose Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: OPTN) stock is to Hold OPTN stock.

Out of 3 analysts, 0 (0%) are recommending OPTN as a Strong Buy, 0 (0%) are recommending OPTN as a Buy, 3 (100%) are recommending OPTN as a Hold, 0 (0%) are recommending OPTN as a Sell, and 0 (0%) are recommending OPTN as a Strong Sell.

If you're new to stock investing, here's how to buy Optinose stock.

What is OPTN's earnings growth forecast for 2025-2027?

(NASDAQ: OPTN) Optinose's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 19.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.81%.

Optinose's earnings in 2025 is -$21,541,000.On average, 3 Wall Street analysts forecast OPTN's earnings for 2025 to be -$31,521,135, with the lowest OPTN earnings forecast at -$55,901,037, and the highest OPTN earnings forecast at -$9,971,536. On average, 3 Wall Street analysts forecast OPTN's earnings for 2026 to be -$14,133,394, with the lowest OPTN earnings forecast at -$43,109,269, and the highest OPTN earnings forecast at $9,770,091.

In 2027, OPTN is forecast to generate -$3,424,568 in earnings, with the lowest earnings forecast at -$28,705,938 and the highest earnings forecast at $21,856,802.

What is OPTN's revenue growth forecast for 2025-2027?

(NASDAQ: OPTN) Optinose's forecast annual revenue growth rate of 20.41% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.16%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.7%.

Optinose's revenue in 2025 is $78,226,000.On average, 2 Wall Street analysts forecast OPTN's revenue for 2025 to be $916,827,375, with the lowest OPTN revenue forecast at $813,334,914, and the highest OPTN revenue forecast at $1,020,319,837. On average, 2 Wall Street analysts forecast OPTN's revenue for 2026 to be $1,144,158,261, with the lowest OPTN revenue forecast at $1,064,537,054, and the highest OPTN revenue forecast at $1,223,779,469.

In 2027, OPTN is forecast to generate $1,376,273,470 in revenue, with the lowest revenue forecast at $1,335,581,543 and the highest revenue forecast at $1,416,965,396.

What is OPTN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: OPTN) forecast ROA is -7.98%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 17.82%.

What is OPTN's Price Target?

According to 3 Wall Street analysts that have issued a 1 year OPTN price target, the average OPTN price target is $9.00, with the highest OPTN stock price forecast at $9.00 and the lowest OPTN stock price forecast at $9.00.

On average, Wall Street analysts predict that Optinose's share price could fall to $9.00 by Mar 21, 2026. The average Optinose stock price prediction forecasts a potential downside of 1.85% from the current OPTN share price of $9.17.

What is OPTN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: OPTN) Optinose's current Earnings Per Share (EPS) is -$2.12. On average, analysts forecast that OPTN's EPS will be -$3.13 for 2025, with the lowest EPS forecast at -$5.55, and the highest EPS forecast at -$0.99. On average, analysts forecast that OPTN's EPS will be -$1.40 for 2026, with the lowest EPS forecast at -$4.28, and the highest EPS forecast at $0.97. In 2027, OPTN's EPS is forecast to hit -$0.34 (min: -$2.85, max: $2.17).

What is OPTN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: OPTN) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.